[go: up one dir, main page]

WO2009021684A3 - Predictive marker for egfr inhibitor treatment - Google Patents

Predictive marker for egfr inhibitor treatment Download PDF

Info

Publication number
WO2009021684A3
WO2009021684A3 PCT/EP2008/006523 EP2008006523W WO2009021684A3 WO 2009021684 A3 WO2009021684 A3 WO 2009021684A3 EP 2008006523 W EP2008006523 W EP 2008006523W WO 2009021684 A3 WO2009021684 A3 WO 2009021684A3
Authority
WO
WIPO (PCT)
Prior art keywords
egfr inhibitor
inhibitor treatment
predictive marker
predictive
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/006523
Other languages
French (fr)
Other versions
WO2009021684A2 (en
Inventor
Paul Delmar
Barbara Klughammer
Verena Lutz
Patricia Mcloughlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2010520472A priority Critical patent/JP5368445B2/en
Priority to US12/672,959 priority patent/US20110184005A1/en
Priority to CN2008801027038A priority patent/CN101827947B/en
Priority to MX2010001583A priority patent/MX2010001583A/en
Priority to BRPI0815543-7A priority patent/BRPI0815543B1/en
Priority to KR20107003253A priority patent/KR101169246B1/en
Priority to ES08785429T priority patent/ES2395881T3/en
Priority to EP20080785429 priority patent/EP2176430B9/en
Priority to AU2008286337A priority patent/AU2008286337B2/en
Priority to PL08785429T priority patent/PL2176430T3/en
Priority to DK08785429T priority patent/DK2176430T5/en
Priority to CA 2695473 priority patent/CA2695473C/en
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to SI200830833T priority patent/SI2176430T1/en
Publication of WO2009021684A2 publication Critical patent/WO2009021684A2/en
Publication of WO2009021684A3 publication Critical patent/WO2009021684A3/en
Priority to IL203647A priority patent/IL203647A/en
Anticipated expiration legal-status Critical
Priority to US13/854,180 priority patent/US9121067B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a biomarker which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
PCT/EP2008/006523 2007-08-14 2008-08-07 Predictive marker for egfr inhibitor treatment Ceased WO2009021684A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
US12/672,959 US20110184005A1 (en) 2007-08-14 2008-08-07 Predictive marker for egfr inhibitor treatment
CN2008801027038A CN101827947B (en) 2007-08-14 2008-08-07 Predictive marker for egfr inhibitor treatment
MX2010001583A MX2010001583A (en) 2007-08-14 2008-08-07 Predictive marker for egfr inhibitor treatment.
BRPI0815543-7A BRPI0815543B1 (en) 2007-08-14 2008-08-07 IN VITRO PROCESS FOR PREDICTING THE RESPONSE OF A PATIENT WITH NON-SMALL CELL LUNG CANCER TO TREATMENT WITH ERLOTINIB, AND IN VITRO USES OF A PTPRF GENE AND ERLOTINIB
KR20107003253A KR101169246B1 (en) 2007-08-14 2008-08-07 Predictive marker for egfr inhibitor treatment
ES08785429T ES2395881T3 (en) 2007-08-14 2008-08-07 Predictive marker for EGFR inhibitor treatment
EP20080785429 EP2176430B9 (en) 2007-08-14 2008-08-07 Predictive marker for egfr inhibitor treatment
PL08785429T PL2176430T3 (en) 2007-08-14 2008-08-07 Predictive marker for egfr inhibitor treatment
AU2008286337A AU2008286337B2 (en) 2007-08-14 2008-08-07 Predictive marker for EGFR inhibitor treatment
JP2010520472A JP5368445B2 (en) 2007-08-14 2008-08-07 Predictive marker for EGFR inhibitor treatment
CA 2695473 CA2695473C (en) 2007-08-14 2008-08-07 Predictive marker for egfr inhibitor treatment
DK08785429T DK2176430T5 (en) 2007-08-14 2008-08-07 Indicator marker for EGFR inhibitor treatment
SI200830833T SI2176430T1 (en) 2007-08-14 2008-08-07 Predictive marker for egfr inhibitor treatment
IL203647A IL203647A (en) 2007-08-14 2010-02-01 Predictive marker for egfr inhibitor treatment
US13/854,180 US9121067B2 (en) 2007-08-14 2013-04-01 Predictive marker for EGFR inhibitor treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114302 2007-08-14
EP07114302.8 2007-08-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/672,959 A-371-Of-International US20110184005A1 (en) 2007-08-14 2008-08-07 Predictive marker for egfr inhibitor treatment
US13/854,180 Continuation US9121067B2 (en) 2007-08-14 2013-04-01 Predictive marker for EGFR inhibitor treatment

Publications (2)

Publication Number Publication Date
WO2009021684A2 WO2009021684A2 (en) 2009-02-19
WO2009021684A3 true WO2009021684A3 (en) 2009-04-16

Family

ID=40227562

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/006523 Ceased WO2009021684A2 (en) 2007-08-14 2008-08-07 Predictive marker for egfr inhibitor treatment

Country Status (14)

Country Link
US (2) US20110184005A1 (en)
EP (1) EP2176430B9 (en)
JP (1) JP5368445B2 (en)
KR (1) KR101169246B1 (en)
CN (1) CN101827947B (en)
AU (1) AU2008286337B2 (en)
CA (1) CA2695473C (en)
DK (1) DK2176430T5 (en)
ES (1) ES2395881T3 (en)
IL (1) IL203647A (en)
MX (1) MX2010001583A (en)
PL (1) PL2176430T3 (en)
SI (1) SI2176430T1 (en)
WO (1) WO2009021684A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2969174B1 (en) * 2010-12-16 2014-03-14 Commissariat Energie Atomique LIGAND SPECIFIC OF LAR PROTEIN

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004111273A2 (en) * 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
WO2005049829A1 (en) * 2003-05-30 2005-06-02 Astrazeneca Uk Limited Process

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525464A (en) * 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) * 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5795716A (en) * 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
JP2006521793A (en) * 2003-02-06 2006-09-28 ゲノミック ヘルス， インコーポレイテッド Gene expression marker responsive to EGFR inhibitor drug
GB0312451D0 (en) * 2003-05-30 2003-07-09 Astrazeneca Uk Ltd Process
US20060234237A1 (en) * 2004-01-08 2006-10-19 Amler Lukas C Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004111273A2 (en) * 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
WO2005049829A1 (en) * 2003-05-30 2005-06-02 Astrazeneca Uk Limited Process

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COLDRENT C D ET AL: "Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non-Small Cell Lung Cancer Cell Lines", MOLECULAR CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH (A AC R), US, vol. 4, 1 July 2006 (2006-07-01), pages 521 - 528, XP003005576, ISSN: 1541-7786 *
GRIDELLI CESARE ET AL: "Erlotinib in non-small cell lung cancer treatment: current status and future development.", THE ONCOLOGIST JUL 2007, vol. 12, no. 7, July 2007 (2007-07-01), pages 840 - 849, XP007905850, ISSN: 1083-7159 *
KAKIUCHI SOJI ET AL: "Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, vol. 13, no. 24, 15 December 2004 (2004-12-15), pages 3029 - 3043, XP002440000, ISSN: 0964-6906 *
KOKUBO Y ET AL: "Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).", BRITISH JOURNAL OF CANCER 9 MAY 2005, vol. 92, no. 9, 9 May 2005 (2005-05-09), pages 1711 - 1719, XP007905848, ISSN: 0007-0920 *
OKANO TETSUYA ET AL: "Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 3, 1 February 2007 (2007-02-01), pages 799 - 805, XP002440001, ISSN: 1078-0432 *
ZHOU BIN-BING S ET AL: "Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer", CANCER CELL, CELL PRESS, US, vol. 10, no. 1, 1 January 2006 (2006-01-01), pages 39 - 50, XP008093928, ISSN: 1535-6108 *

Also Published As

Publication number Publication date
JP2010535524A (en) 2010-11-25
ES2395881T3 (en) 2013-02-15
PL2176430T3 (en) 2013-02-28
DK2176430T5 (en) 2013-09-08
EP2176430B9 (en) 2013-07-24
CA2695473A1 (en) 2009-02-19
BRPI0815543A2 (en) 2013-03-12
ES2395881T9 (en) 2013-09-06
KR20100037634A (en) 2010-04-09
AU2008286337B2 (en) 2011-10-27
WO2009021684A2 (en) 2009-02-19
US20110184005A1 (en) 2011-07-28
CN101827947A (en) 2010-09-08
KR101169246B1 (en) 2012-08-03
SI2176430T1 (en) 2013-01-31
AU2008286337A1 (en) 2009-02-19
US20130210843A1 (en) 2013-08-15
IL203647A (en) 2013-02-28
MX2010001583A (en) 2010-03-15
JP5368445B2 (en) 2013-12-18
CN101827947B (en) 2013-11-13
EP2176430B1 (en) 2012-09-19
DK2176430T3 (en) 2012-10-08
EP2176430A2 (en) 2010-04-21
CA2695473C (en) 2013-10-01
US9121067B2 (en) 2015-09-01

Similar Documents

Publication Publication Date Title
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2010146059A3 (en) Biomarkers for igf-1r inhibitor therapy
WO2008031551A3 (en) Non-neuroendocrine cancer therapy
IL196470A (en) Antagonist antibody for the treatment of cancer
IL192794A (en) Method of predicting positive clinical outcome for a human subject diagonsed with colorectal cancer following surgical resection of the cancer
WO2010124264A3 (en) Genetic variants in angiogenesis pathway associated with clinical outcome
EP2271931A4 (en) BIOMARKERS OF MICROARN-BASED TISSUE LESIONS
EP2040753B8 (en) Progastrin inhibitors in the treatment of colon cancer
WO2008118413A3 (en) Methods for detecting coronary artery disease
WO2008054598A8 (en) Panel of biomarkers for prediction of fti efficacy
WO2010015538A3 (en) Predictive marker for egfr inhibitor treatment
MX2010001571A (en) Predictive markers for egfr inhibitor treatment.
WO2008115710A3 (en) Biomarkers for cancer
WO2009021683A3 (en) Predictive marker for egfr inhibitor treatment
MX343803B (en) Ipp complex as marker for erlotinib treatment.
MX2010001573A (en) Predictive marker for egfr inhibitor treatment.
EP2063271A4 (en) TUMOR MARKER OF KIDNEY CANCER AND METHOD OF DETERMINING THE SURGERY OF KIDNEY CANCER
WO2009021684A3 (en) Predictive marker for egfr inhibitor treatment
MX2010001570A (en) Predictive marker for egfr inhibitor treatment.
WO2009021681A3 (en) Egfr inhibitor treatment marker
MX2010001572A (en) Predictive marker for egfr inhibitor treamtent.
MX2010001579A (en) Predictive marker for egfr inhibitor treatment.
MX2010001580A (en) Predictive marker for egfr inhibitor treatment.
AU2007907088A0 (en) Use of Naltrexone for Treating Alzheimers Disease
WO2011079273A3 (en) Methods and compositions for cardiovascular diseases and conditions

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880102703.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08785429

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008286337

Country of ref document: AU

Ref document number: 2008785429

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 203647

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2695473

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 231/MUMNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/001583

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2010520472

Country of ref document: JP

Ref document number: 12672959

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20107003253

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008286337

Country of ref document: AU

Date of ref document: 20080807

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0815543

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100212